Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.06, Bloomberg Earnings reports.

Shares of Marinus Pharmaceuticals (NASDAQ MRNS) traded up 1.64% during midday trading on Wednesday, hitting $1.86. The company had a trading volume of 695,122 shares. Marinus Pharmaceuticals has a 12 month low of $0.82 and a 12 month high of $2.73. The stock’s 50-day moving average price is $1.50 and its 200-day moving average price is $1.40. The company’s market cap is $41.70 million.

WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/02/marinus-pharmaceuticals-inc-mrns-releases-quarterly-earnings-results-beats-expectations-by-0-06-eps.html.

Separately, ValuEngine raised Marinus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, June 20th.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Earnings History for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.